Silence Therapeutics

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Retrieved on:

Friday, February 23, 2024

Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Therapy, AstraZeneca, Metabolism, SVP, Silence Therapeutics, Polycythemia, RNA, DSM-IV codes, Clinical trial, Small RNA, Biopharmaceutical, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

Key Points:

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.
“This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the clinic from our mRNAi GOLD™ platform,” said Craig Tooman, President and CEO of Silence.
Silence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination.

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

Retrieved on:

Wednesday, January 17, 2024

SLN, Regenerative medicine, Fertility, Therapy, PTC, PTC Therapeutics, Flagship Pioneering, Partnership, Doctor of Pharmacy, Business, Business development, MBA, Silence Therapeutics, Johnson & Johnson, Publicis, Doctor of Philosophy, Biomedical Research, Nanobiotix, Management

NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.

Key Points:

NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.
“NAYA is thrilled to welcome new board members with outstanding executive and entrepreneurial track records,” commented NAYA CEO Dr. Daniel Teper.
She is currently Executive Engagement Lead at Publicis, the 2nd largest communications group in the world, where she launched multiple brands as Chief Marketing Officer.
He previously held several leadership positions in corporate and business development and partnerships at Sanofi.

Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides

Retrieved on:

Monday, November 20, 2023

He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.

Key Points:

He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.
His appointment also reflects Moa’s use of cutting-edge biotechnology processes to identify, understand and develop next-generation herbicides with game-changing speed and accuracy.
Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth.
Dr. Virginia Corless, Chief Executive Officer of Moa Technology, says:
“Moa is tackling a major crisis that threatens farmers’ livelihoods and global food security.

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Retrieved on:

Friday, December 1, 2023

Biotechnology, Pharmaceutical, Health, Molecular design software, Growth, Doctor of Philosophy, Silence Therapeutics, Therapy, Multimedia, Small RNA, MD, Pharmaceutical industry, Silence, Research

View the full release here: https://www.businesswire.com/news/home/20231201341026/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20231201341026/en/
Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics plc (Photo: Business Wire)
“I want to congratulate Curtis and Marie on their well-deserved promotions,” said Steven Romano, MD, Head of Research and Development at Silence.
Curtis’ broad experience leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence’s next phase of growth.
With our expanding mRNAi GOLD™ platform programs and commitment to advancing scientific research, I am also looking forward to continuing to collaborate closely with Marie.
Her extensive work in oligonucleotide therapeutics is impressive and we are very fortunate to have her leading our efforts to innovate and further expand our footprint as a global siRNA leader.”

Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on:

Friday, November 17, 2023

Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points:

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Galapagos appoints Simon Sturge to its Board of Directors

Retrieved on:

Tuesday, September 19, 2023

Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation.

Key Points:

Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation.
Mr. Sturge brings over 40 years of international biotech and pharma experience with leadership positions at Merck KGaA and Boehringer Ingelheim.
Mr. Sturge is currently Chairman of the Board of Directors of MoonLake Immunotherapeutics, Precerix and Mediar Therapeutics.
“On behalf of Galapagos’ Board of Directors, I am very pleased to welcome Simon to our Board,” said Dr. Paul Stoffels1, CEO and Chairman of Galapagos.

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Retrieved on:

Tuesday, July 11, 2023

Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Hansoh Pharmaceutical, Silence Therapeutics, AstraZeneca, Small RNA, Sirna Therapeutics, Therapy, News, Pharmaceutical industry, Silence

“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silence.

Key Points:

“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silence.
“Today’s news follows the $10.0 million milestone payment we achieved in our AstraZeneca collaboration in May and reflects our ongoing efforts to advance our partnered pipeline.
Hansoh made a $16 million upfront payment to Silence and the Company is eligible to receive up to $1.3 billion in development, regulatory and commercial milestones.
Today’s announcement represents the second and third research milestone payments achieved under the collaboration.

Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth

Retrieved on:

Thursday, June 15, 2023

Heart failure, LCS, CSO, Karlsruhe Institute of Technology, Biotechnology, Silence Therapeutics, Research, Doctor of Philosophy, AstraZeneca, Molecular biology, FAAB, Patient, Growth, Health, Phase, Long, Pharmaceutical industry, Long COVID

BERLIN, June 15, 2023 /PRNewswire/ -- Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is pleased to announce the appointment of its new Chief Executive Officer (CEO), Dr. Oliver von Stein. He assumes the role with immediate effect and will work closely with Berlin Cures' co-founder Dr. Johannes Müller, who will hand over his CEO duties to drive the company's research activities as the new Chief Science Officer (CSO). Dr. Müller, an accomplished physician, researcher, and innovator, has been instrumental in the development of BC 007.

Key Points:

"We are excited to welcome Dr. Oliver von Stein as our new CEO to drive the next phase of innovation and growth at Berlin Cures," said Rainer Böhm, Chairman of the Board of Directors.
By tackling the root cause, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue."
Dr. Oliver von Stein said: "I'm truly honored to be joining the esteemed team at Berlin Cures during this pivotal moment.
Dr. Johannes Mueller added: "I am very pleased to welcome Dr. Oliver von Stein to Berlin Cures.

Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth

Retrieved on:

Thursday, June 15, 2023

BERLIN, June 15, 2023 /PRNewswire/ -- Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is pleased to announce the appointment of its new Chief Executive Officer (CEO), Dr. Oliver von Stein. He assumes the role with immediate effect and will work closely with Berlin Cures' co-founder Dr. Johannes Müller, who will hand over his CEO duties to drive the company's research activities as the new Chief Science Officer (CSO). Dr. Müller, an accomplished physician, researcher, and innovator, has been instrumental in the development of BC 007.

Key Points:

"We are excited to welcome Dr. Oliver von Stein as our new CEO to drive the next phase of innovation and growth at Berlin Cures," said Rainer Böhm, Chairman of the Board of Directors.
By tackling the root cause, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue."
Dr. Oliver von Stein said: "I'm truly honored to be joining the esteemed team at Berlin Cures during this pivotal moment.
Dr. Johannes Mueller added: "I am very pleased to welcome Dr. Oliver von Stein to Berlin Cures.

Mithra - Letter to Shareholders and Corporate Update

Retrieved on:

Thursday, May 25, 2023

Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024

Key Points:

Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024
Liege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the "Company" or "Mithra"), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon.
I accepted the role because my analysis revealed strong fundamentals and tremendous potential to create significant value for Mithra shareholders.
Collectively, the Mithra leadership understands that our ability to create value for our shareholders is a primary directive that goes hand in hand with developing medicines for women.
I look forward to continuing with increased transparency and regular communications to providing updates on our progress to you, our shareholders.